Anticoagulant - Related Links


Antithrombotic agents
Drug class
ATC code B01
External links
MeSH D005343
AHFS/ Drug Classes

Anticoagulants (antithrombics) are a class of drugs that work to prevent the coagulation (clotting) of blood. Such substances occur naturally in leeches and blood-sucking insects. A group of pharmaceuticals called anticoagulants can be used as an injection into human beings as a medication for thrombotic disorders. Some anticoagulants are used in medical equipment, such as test tubes, blood transfusion bags, and renal dialysis equipment.


Anticoagulants reduce blood clotting which can help prevent deep vein thrombosis, pulmonary embolism, myocardial infarction and ischemic stroke.

Therapeutic uses of anticoagulants include atrial fibrillation, pulmonary embolism, deep vein thrombosis, venous thromboembolism, congestive heart failure, stroke, myocardial infarction, and genetic or acquired hypercoagulability.

The decision to begin therapeutic anticoagulation often involves the use multiple bleeding risk predictable outcome tools clinicians use as non-invasive pre-test stratifications due to the potential for bleeds while on blood thinning agents. Among these tools are HAS-BLED,[1] ATRIA,[2] and CHA2DS2-VASc.[3]

Adverse effects

Patients aged 80 years or more may be especially susceptible to bleeding complications, with a rate of 13 bleeds per 100 person-years.[4] These oral anticoagulants are used widely as poisons for mammalian pests, especially rodents. (For details, see rodenticide and warfarin.) Depletion of vitamin K by Coumadin therapy increases risk of arterial calcification and heart valve calcification, especially if too much vitamin D is present.[5]


Foods and food supplements with blood-thinning effects include nattokinase, lumbrokinase, beer, bilberry, celery, cranberries, fish oil, garlic, ginger, ginkgo, ginseng, green tea, horse chestnut, licorice, niacin, onion, papaya, pomegranate, red clover, soybean, St. John’s wort, turmeric, wheatgrass, and willow bark.[6] Many herbal supplements have blood-thinning properties, such as danshen and feverfew. Multivitamins that do not interact with clotting are available for patients on anticoagulants.

However, some foods and supplements encourage clotting. These include alfalfa, avocado, cat's claw, coenzyme Q10, and dark leafy greens such as spinach. Their intake should be avoided whilst taking anticoagulants or, if coagulability is being monitored, their intake should be kept approximately constant so that anticoagulant dosage can be maintained at a level high enough to counteract this effect without fluctuations in coagulability.

Grapefruit interferes with some anticoagulant drugs, increasing the amount of time it takes for them to be metabolized out of the body, and so should be eaten only with caution when on anticoagulant drugs.

Anticoagulants are often used to treat acute deep vein thrombosis. People using anticoagulants to treat this condition should avoid using bed rest as a complementary treatment because there are clinical benefits to continuing to walk and remaining mobile while using anticoagulants in this way.[7] Bed rest while using anticoagulants can harm patients in circumstances in which it is not medically necessary.[7]

Physical and chemical properties

The novel oral anticoagulants (NOACs) including dabigatran, rivaroxaban, and apixaban have been shown to be as good or better than the coumarins (vitamin K antagonists) with less serious side effects.[8] The newer anticoagulants (NOACs), are more expensive than the traditional ones and should be used with care in patients with kidney problems. Additionally, there is no antidotum yet, so it is difficult to stop their effects in the body in cases of emergency (accidents, urgent surgery). Good adherence to this therapy is of paramount importance for optimal effect.

Coumarins (vitamin K antagonists)

Further information: Vitamin K antagonist

These oral anticoagulants are derived from coumarin, which is found in many plants. A prominent member of this class is warfarin (Coumadin). It takes at least 48 to 72 hours for the anticoagulant effect to develop. Where an immediate effect is required, heparin must be given concomitantly. These anticoagulants are used to treat patients with deep-vein thrombosis (DVT), pulmonary embolism (PE) and to prevent emboli in patients with atrial fibrillation (AF), and mechanical prosthetic heart valves. Other examples are acenocoumarol and phenprocoumon, atromentin and phenindione.

The coumarins brodifacoum and difenacoum are used as rodenticides, but are not used medically.

Heparin and derivative substances

Heparin is a biological substance, usually made from pig intestines. It works by activating antithrombin III, which blocks thrombin from clotting blood. Heparin can be used in vivo (by injection), and also in vitro to prevent blood or plasma clotting in or on medical devices. In venipuncture, Vacutainer brand blood collecting tubes containing heparin usually have a green cap.

Low molecular weight heparin

Low molecular weight heparin, a more highly processed product, is useful as it does not require monitoring of the APTT coagulation parameter (it has more predictable plasma levels) and has fewer side effects.

Synthetic pentasaccharide inhibitors of factor Xa

  • Fondaparinux is a synthetic sugar composed of the five sugars (pentasaccharide) in heparin that bind to antithrombin. It is a smaller molecule than low molecular weight heparin.
  • Idraparinux

Direct factor Xa inhibitors

Main article: Direct Xa inhibitor

Drugs such as rivaroxaban, apixaban and edoxaban work by inhibiting factor Xa directly (unlike the heparins and fondaparinux, which work via antithrombin activation). Also betrixaban (LY517717) from Portola Pharmaceuticals, darexaban (YM150) from Astellas and more recent TAK-442 letaxaban (Takeda) and eribaxaban (PD0348292) (Pfizer). The development of darexaban was discontinued in September 2011: in a trial for prevention of recurrences of myocardial infarction in top of dual antiplatelet therapy, the drug did not demonstrate effectiveness and the risk of bleeding was increased by approximately 300%.[9] The development of letaxaban was discontinued for acute coronary syndrome in May 2011 following negative results from a Phase II study.[10]

Direct thrombin inhibitors

Another type of anticoagulant is the direct thrombin inhibitor.[11] Current members of this class include the bivalent drugs hirudin, lepirudin, and bivalirudin; and the monovalent drugs argatroban and dabigatran. An oral direct thrombin inhibitor, ximelagatran (Exanta) was denied approval by the Food and Drug Administration (FDA) in September 2004 [1] and was pulled from the market entirely in February 2006 after reports of severe liver damage and heart attacks. [2] In November 2010, dabigatran was approved by the FDA to treat atrial fibrillation.

Antithrombin protein therapeutics

The antithrombin protein itself is used as a protein therapeutic that can be purified from human plasma[12] or produced recombinantly (for example, Atryn, which is produced in the milk of genetically modified goats.[13][14])

Antithrombin is approved by the FDA as an anticoagulant for the prevention of clots before, during, or after surgery or birthing in patients with hereditary antithrombin deficiency.[12][14]

Other types of anticoagulants

Many other anticoagulants exist, for use in research and development, diagnostics, or as drug candidates.

Society and culture

Warfarin (Coumadin) is the main agent used in the US and UK.[15] Acenocoumarol and phenprocoumon are used more commonly outside the US and the UK.

Laboratory use

Laboratory instruments, blood transfusion bags, and medical and surgical equipment will get clogged up and become nonoperational if blood is allowed to clot. In addition, test tubes used for laboratory blood tests will have chemicals added to stop blood clotting. Apart from heparin, most of these chemicals work by binding calcium ions, preventing the coagulation proteins from using them.

  • Ethylene Diamine Tetra Acetic Acid (EDTA) strongly and irreversibly chelates (binds) calcium ion to prevent blood from clotting.
  • Citrate is in liquid form in the tube and is used for coagulation tests, as well as in blood transfusion bags. It binds the calcium, but not as strongly as EDTA. Correct proportion of this anticoagulant to blood is crucial because of the dilution, and it can be reversed with the addition of calcium. It can be in the form of sodium citrate or acid-citrate-dextrose.
  • Oxalate has a mechanism similar to that of citrate. It is the anticoagulant used in fluoride oxalate tubes used to determine glucose and lactate levels.

See also


  1. ^ "HAS-BLED Score for Major Bleeding risk". MDCalc. Retrieved 2014-08-15. 
  2. ^ "ATRIA Bleeding Risk". MDCalc. Retrieved 2014-08-15. 
  3. ^ "CHA2DS2-VASc". MDCalc. Retrieved 2014-08-15. 
  4. ^ Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S (2007). "Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation". Circulation 115 (21): 2689–96. PMID 17515465. doi:10.1161/CIRCULATIONAHA.106.653048. 
  5. ^ Adams J, Pepping J (1 Aug 2005). "Vitamin K in the treatment and prevention of osteoporosis and arterial calcification" (PDF). American Journal of Health-System Pharmacy 62 (15): 1574–81. PMID 16030366. doi:10.2146/ajhp040357. Retrieved 2012-10-03. 
  6. ^ Wittkowsky AK (September 2001). "Drug interactions update: drugs, herbs, and oral anticoagulation". J. Thromb. Thrombolysis 12 (1): 67–71. PMID 11711691. doi:10.1023/A:1012742628628. 
  7. ^ a b American Physical Therapy Association (15 September 2014), "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation (American Physical Therapy Association), retrieved 15 September 2014 , which cites
    • Aissaoui, Nadia; Martins, Edith; Mouly, Stéphane; Weber, Simon; Meune, Christophe (2009). "A meta-analysis of bed rest versus early ambulation in the management of pulmonary embolism, deep vein thrombosis, or both". International Journal of Cardiology 137 (1): 37–41. ISSN 0167-5273. doi:10.1016/j.ijcard.2008.06.020. 
    • Anderson, Cathy M.; Overend, Tom J.; Godwin, Julie; Sealy, Christina; Sunderji, Aisha (2009). "Ambulation after Deep Vein Thrombosis: A Systematic Review". Physiotherapy Canada 61 (3): 133–140. ISSN 0300-0508. doi:10.3138/physio.61.3.133. 
  8. ^ Werdan, Karl; Braun-Dullaeus, Rüdiger; Presek, Peter (Aug 2013). "Anticoagulation in Atrial Fibrillation: NOAC’s the Word". Deutsches Ärzteblatt International 110 (31-32): 523–524. PMC 3782018. doi:10.3238/arztebl.2013.0523. Retrieved 26 October 2014. Things have changed dramatically with the introduction of the new oral anticoagulants (NOACs) — dabigatran, a factor IIa (thrombin) inhibitor, and the factor Xa inhibitors rivaroxaban and apixaban. Clinical trials have shown them therapeutically superior, or at least non-inferior, to VKAs, with less serious side effects. 
  9. ^ Steg, PG; Mehta, SR; Jukema, JW; Lip, GY; Gibson, CM; Kovar, F; Kala, P; Garcia-Hernandez, A; Renfurm, RW; Granger, CB; Ruby-1, Investigators (2011). "RUBY-1: A randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome". European heart journal 32 (20): 2541–54. PMC 3295208. PMID 21878434. doi:10.1093/eurheartj/ehr334. 
  10. ^ First Time European Approval for Xarelto in ACS
  11. ^ Di Nisio M, Middeldorp S, Büller HR (2005). "Direct thrombin inhibitors". N. Engl. J. Med. 353 (10): 1028–40. PMID 16148288. doi:10.1056/NEJMra044440. 
  12. ^ a b Thrombate III label
  13. ^ FDA website for ATryn (BL 125284)
  14. ^ a b Antithrombin (Recombinant) US Package Insert ATryn for Injection February 3, 2009
  15. ^ Ron Winslow; Avery Johnson (2007-12-10). "Race Is on for the Next Blood Thinner". Wall Street Journal. p. A12. Retrieved 2008-01-06. a market now dominated by one of the oldest mainstay pills in medicine: the blood thinner warfarin. At least five next-generation blood thinners are in advanced testing to treat or prevent potentially debilitating or life-threatening blood clots in surgery and heart patients. First candidates could reach the market in 2009. 

External links